Pcsk9 - proprotein convertase subtilisin/kexin type 9 Gene

Also Known as FH3; PC9; Narc1; HCHOLA3

Species: Mus musculus

Gene Type: protein coding
Gene ID: 100102

Summary

Enables Apolipoprotein binding activity; lipoprotein particle binding activity; and low-density lipoprotein particle receptor binding activity. Involved in several processes, including cellular response to Insulin stimulus; cellular response to starvation; and regulation of neuron apoptotic process. Acts upstream of or within several processes, including low-density lipoprotein receptor particle metabolic process; regulation of low-density lipoprotein particle receptor catabolic process; and triglyceride metabolic process. Located in COPII-coated ER to Golgi transport vesicle; endoplasmic reticulum; and extracellular space. Is expressed in several structures, including alimentary system; cerebellum; genitourinary system; liver; and telencephalon. Human ortholog(s) of this gene implicated in familial hypercholesterolemia and hypobetalipoproteinemia. Orthologous to human PCSK9 (proprotein convertase subtilisin/kexin type 9). [provided by Alliance of Genome Resources, Apr 2022]

Pcsk9 Products (1)

mRNA Protein Name
NM_153565.2 NP_705793.1 proprotein convertase subtilisin/kexin type 9 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables apolipoprotein binding IDA
IDA: Inferred from direct assay
22580899 MGI
enables low-density lipoprotein particle binding IDA
IDA: Inferred from direct assay
22580899 MGI
enables low-density lipoprotein particle receptor binding IDA
IDA: Inferred from direct assay
17080197 MGI
enables very-low-density lipoprotein particle binding IDA
IDA: Inferred from direct assay
22580899 MGI
Biological Process GO Annotation Evidence References Source
involved in cellular response to insulin stimulus IDA
IDA: Inferred from direct assay
16407292 MGI
involved in cellular response to starvation IDA
IDA: Inferred from direct assay
16407292 MGI
acts upstream of or within cholesterol metabolic process IDA
IDA: Inferred from direct assay
17242417 MGI
involved in kidney development IEP
IEP: Inferred from expression pattern
12552133 MGI
acts upstream of or within lipoprotein metabolic process IDA
IDA: Inferred from direct assay
17242417 MGI
involved in liver development IEP
IEP: Inferred from expression pattern
12552133 MGI
acts upstream of or within low-density lipoprotein receptor particle metabolic process IDA
IDA: Inferred from direct assay
17242417 MGI
involved in neurogenesis IEP
IEP: Inferred from expression pattern
12552133 MGI
involved in neuron differentiation IDA
IDA: Inferred from direct assay
16893422 MGI
involved in neuron differentiation IMP
IMP: Inferred from mutant phenotype
12552133 MGI
acts upstream of or within phospholipid metabolic process IDA
IDA: Inferred from direct assay
17242417 MGI
acts upstream of or within regulation of low-density lipoprotein particle receptor catabolic process IMP
IMP: Inferred from mutant phenotype
15741654 MGI
involved in regulation of neuron apoptotic process IMP
IMP: Inferred from mutant phenotype
22481440 MGI
acts upstream of or within triglyceride metabolic process IDA
IDA: Inferred from direct assay
17242417 MGI
Cellular Component GO Annotation Evidence References Source
located in COPII-coated ER to Golgi transport vesicle IDA
IDA: Inferred from direct assay
23580231 MGI
located in endoplasmic reticulum IDA
IDA: Inferred from direct assay
23580231 MGI
located in extracellular region IDA
IDA: Inferred from direct assay
12552133 MGI
located in extracellular space IDA
IDA: Inferred from direct assay
17080197 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

proprotein convertase subtilisin/kexin type 9

  • NARC-1

  • convertase subtilisin

  • neural apoptosis regulated convertase 1

  • proprotein convertase 9

  • proprotein convertase PC9

  • subtilisin/kexin-like protease PC9

Recombinant Pcsk9 Proteins

Cat. No. Product Name Accession Purity
HY-P71189 PCSK9 Protein, Mouse (HEK293, His, solution) Q80W65 (Q35-Q155&S156-Q694) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P78825 PCSK9 Protein, Mouse (Biotinylated, HEK293, His-Avi) AAH38085 (Q35-Q694) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-132591A Inclisiran sodium Inhibitor 99.08% Unkown
HY-132591 Inclisiran Inhibitor 99.48% Unkown
HY-132591C Inclisiran sodium scrambled negative control Inhibitor / Unkown
Inhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9928 Alirocumab Inhibitor 97.00% Unkown
HY-P99696 Lerodalcibep / Unkown

Clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-148673 Laroprovstat Inhibitor 99.93% Phase 3
HY-12090 Anacetrapib Inhibitor 99.25% Phase 3
HY-158825 Cepadacursen sodium / Phase 2
HY-148687A SPC5001 sodium Inhibitor 98.89% Phase 1
HY-163794 DC371739 Inhibitor 95.56% Phase 1
HY-112598A PF-06815345 hydrochloride Inhibitor 98.15% Phase 1
Inhibitory Antibodies (8)
Cat. No. Product Name Effect
Purity Phase
HY-P99822 Recaticimab Inhibitor 99.71% Phase 4
HY-P99552 Tafolecimab Inhibitor 95.04% Phase 4
HY-P99187 Bococizumab Inhibitor 99.80% Phase 3
HY-P99871 Ebronucimab Inhibitor / Phase 3
HY-P99773 Ongericimab Inhibitor / Phase 3
HY-P99626 Frovocimab Inhibitor 96.78% Phase 2
HY-P99251 Lodelcizumab Inhibitor ≥99.0% Phase 1
HY-P99251 Lodelcizumab Inhibitor ≥99.0% Phase 1

Pre-clinical Phase

Bioactive Molecules (70)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P4153 Enlicitide chloride Inhibitor 99.11% Unkown
HY-120088A PF-06446846 hydrochloride Inhibitor 99.44% Unkown
HY-143219 SS-Inclisiran sodium Inhibitor 97.91% Unkown
HY-12402 SBC-115076 Inhibitor 99.28% Unkown
HY-P2276 Pep2-8 Inhibitor 99.74% Unkown
HY-W510159 5-O-Methylembelin Inhibitor 99.43% Unkown
HY-143220 SS(no Galnac)-Inclisiran sodium Inhibitor 98.05% Unkown
HY-150223 GalNAc unconjugated/naked Inclisiran Inhibitor 98.83% Unkown
HY-152221 PCSK9-IN-10 Inhibitor 98.89% Unkown
HY-152223 PCSK9-IN-11 Inhibitor 99.30% Unkown
HY-101354 R-IMPP Inhibitor 99.93% Unkown
HY-157434 PCSK9-IN-23 Inhibitor 99.57% Unkown
HY-148758 PCSK9-IN-13 Inhibitor 98.00% Unkown
HY-130245 PCSK9 degrader 1 Degrader 98.33% Unkown
HY-101832 SBC-110736 Inhibitor 99.55% Unkown
HY-142026 Vitisin A Inhibitor 97% Unkown
HY-141714 SBC-115337 Inhibitor 98.02% Unkown
HY-158827A AZD8233 sodium 94.99% Unkown
HY-120088 PF-06446846 Inhibitor 98.35% Unkown
HY-162562 E28362 Inhibitor 94.51% Unkown
HY-161939 7030B-C5 Inhibitor 99.78% Unkown
HY-P2276A Pep2-8 TFA Inhibitor 98.78% Unkown
HY-161940 PCSK9-IN-30 Inhibitor / Unkown
HY-147252A Bezeparsen sodium Inhibitor 95.21% Unkown
HY-148687 SPC5001 Inhibitor 95.11% Unkown
HY-112598 PF-06815345 Inhibitor / Unkown
HY-159595 PCSK9-IN-29 Inhibitor 99.44% Unkown
HY-W1126955 Enlicitide decanoate Inhibitor / Unkown
HY-148626 CVI-LM001 Inhibitor / Unkown
HY-147252 Bezeparsen Inhibitor / Unkown
HY-RS10177 PCSK9 Human Pre-designed siRNA Set A Inhibitor / Unkown
HY-148689 SPC4061 Inhibitor / Unkown
HY-149310 Dim16 Inhibitor / Unkown
HY-161435 PCSK9-IN-27 Inhibitor / Unkown
HY-153453 PCSK9-IN-17 Inhibitor / Unkown
HY-P11071 PCSK9 Inhibitor, EGF-A Inhibitor / Unkown
HY-179106 PCSK9-IN-34 Inhibitor / Unkown
HY-161434 PCSK9-IN-26 Inhibitor / Unkown
HY-153452 PCSK9-IN-16 Inhibitor / Unkown
HY-130245A (R,R)-PCSK9 degrader 1 Degrader / Unkown
HY-N10702 PCSK9-IN-9 Inhibitor / Unkown
HY-134482 PCSK9-IN-1 Inhibitor / Unkown
HY-148687C SPC5001 sodium scrambled negative control Inhibitor / Unkown
HY-141724 PCSK9 ligand 1 Inhibitor / Unkown
HY-163141 PCSK9-IN-24 Inhibitor / Unkown
HY-153454 PCSK9-IN-18 Inhibitor / Unkown
HY-P11216 Pep2-8 analogue 18 Inhibitor / Unkown
HY-153391 PCSK9-IN-14 Inhibitor / Unkown
HY-146085 PCSK9 modulator-4 Modulator / Unkown
HY-160036 PCSK9-IN-22 Inhibitor / Unkown
HY-128334 PCSK9 modulator-2 Modulator / Unkown
HY-148689C SPC4061 sodium scrambled negative control Inhibitor / Unkown
HY-176043 PCSK9 autophagic degrader 2 Degrader / Unkown
HY-146084 PCSK9 modulator-3 Modulator / Unkown
HY-161942 PCSK9-IN-31 Inhibitor / Unkown
HY-153451 PCSK9-IN-15 Inhibitor / Unkown
HY-148689A SPC4061 sodium Inhibitor / Unkown
HY-161941 MeIm Inhibitor / Unkown
HY-155006 PCSK9-IN-19 Inhibitor / Unkown
HY-147252C Bezeparsen sodium scrambled negative control Inhibitor / Unkown
HY-18778C Obicetrapib hemicalcium Inhibitor / Unkown
HY-164344 PCSK9 allosteric binder-1 / Unkown
HY-168156 PCSK9-IN-32 Inhibitor / Unkown
HY-158825A Cepadacursen sodium scrambled negative control / Unkown
HY-175189 PCSK9-IN-33 Inhibitor / Unkown
HY-161938 BRD8518 Inhibitor / Unkown
HY-158827 AZD8233 / Unkown
HY-158827B AZD8233 sodium scrambled negative control / Unkown
HY-155415 PCSK9-IN-20 Inhibitor / Unkown
HY-149310A Dim16 hydrochloride Inhibitor / Unkown
Inhibitory Antibodies (6)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P9928A Alirocumab (anti-PCSK9) Inhibitor 98.24% Unkown
HY-P99816 Ralpancizumab Inhibitor 96.23% Unkown
HY-P991721 Ticalicibart Inhibitor 99.028% Unkown
HY-P992407 MEDI-4166 / Unkown
HY-P991343 ALD306 Inhibitor / Unkown
HY-P990485 Anti-PCSK9 Antibody Inhibitor 98.39% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Pcsk9 NCBI NCBI:255738